Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.